+ R: + + NS L: + R: + NS + + + + + + + + + + + + + + + + + + + + NS NS NS NS NS NS NS Mast/ALND Mast/SLNB BCS BCS BCS HT NS NS NS NS 20 NS 101 80 90 NED NS NED NED NED + + + + + + + + + + + + + BCS/ SLNB Mast/ALND BCS HT Ch Ch 12 NS NS NED NS NS + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + NS NS + + NS + + + + + + + NS NS + NS + + NS NS NS NS NS NS NS NS NS + NS NS NS NS NS NS Ch NS NS Ch Ch Mast/ALND BCS BCS Mast/ALND Mast/ALND Mast Mast/ALND BCS/ALND NS NS Mast BCS BCS BCS Mast/SLNB/Re Mast/SLNB BCS/ALND Mast/ALND Mast/ALND Mast/ALND BCS/ALND BCS/SLNB BCS NS NS NS NS NS Ch HT Ch/RT NS NS HT Ch/RT Ch/RT Ch/RT Ch HT Ch/RT Ch Ch Ch Ch RT RT 54 NS NS NS NS 14 12 18 34 43 NS 48 20 6 NS 36 18 9 8 12 three NS 18 NED NED NED NED NS D-N0S NED NED NED NED AWM NED D-NOS AWM NS NED NED D-NOS NED AWM D-NOS NS NEDAngarita et al. Planet Journal of Surgical Oncology 2013, 11:128 http://wjso/content/11/1/T1N0M0 Each + TisN0M0 TisN0M0 TisN0M0 + + +Page 5 ofTable 1 Summary of principal neuroendocrine carcinoma with the breast circumstances published inside the indexed literature (n=83)a (Continued)74/F 28/F 30/F 58/F 36/F 38/F 60/F 42/F 43/F 35/F 70/F 72/F 62/F 38/F 73/F 43/F 42/F 39/F 33/F 36/F 68/F (2012) [Present case]aAngarita et al. Globe Journal of Surgical Oncology 2013, 11:128 http://wjso/content/11/1/R R L R L R L L R R L R L R R L L R R L R R0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.four 0.five 0.5 0.7 1.five two.five 2.TisN0M0 TisN0M0 TisN0M0 TisN0M0 TisN0M0 TisN0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N1M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T2N0M0 T4aN0M+ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + -NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS -NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS Ch/RTBCS Mast BCS BCS BCS Mast BCS Mast BCS BCS Mast Mast BCS BCS Mast BCS BCS Mast Mast BCS Mast Mast/ALNDNS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS Ch/HT91 77 86 96 64 69 84 73 80 one hundred 93 66 88 85 71 86 96 74 92 99 68NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED AWM51/FStudies incorporated in this table are those accessible in PubMed as of May well 31, 2012.NH2-PEG3-C2-NH-Boc Data Sheet Papers that had been excluded from this summary are those in which information was not supplied explicitly inside the description in the case report or simply because the outcomes had been grouped into cohorts [12,49,57].Cryptand 2.2.2 Chemscene b Obtained either from clinical history or the final pathology report; for multifocal or multicentric disease the largest tumor was registered.PMID:33745403 ALND, axillary lymph node dissection; AWM, alive with metastatic illness; B, bilateral; BCS, breast conserving surgery; CgA/B, chromogranin A and/or B; Ch, chemotherapy; D-NOS, dead, but trigger not otherwise specified; DOD, dead of other disease; ER, estrogen receptors; F, female; GML, Grimelius staining; HT, hormone therapy; IHC, immunohistochemistry; IS, breast in situ component; LR, local recurrence; M, male; Mast, mastectomy; MC, multicentric; MF, multifocal; NED; no evidence of illness; NS, details not specified; NSE, neuron-specific enolase; NSG, neurosecretory granules; PR, progesterone receptors; R, proper; Re, reconstruction; RT, radiation therapy; SLNB, sentinel lymph node biopsy; Syn, synaptophysin.Page 6 ofAngarita et al. World Journal of Surgical.